HomeSH0 • FRA
add
Shionogi & Co Ltd
Previous close
€42.80
Day range
€42.60 - €42.60
Year range
€36.60 - €48.60
Market cap
2.11T JPY
Avg Volume
19.00
P/E ratio
-
Dividend yield
-
Primary exchange
TYO
Financials
Income Statement
Revenue
Net income
| (JPY) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 106.28B | -43.34% |
Operating expense | 51.13B | -1.90% |
Net income | 36.63B | -63.54% |
Net profit margin | 34.47 | -35.64% |
Earnings per share | — | — |
EBITDA | 45.20B | -63.12% |
Effective tax rate | 25.86% | — |
Balance Sheet
Total assets
Total liabilities
| (JPY) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 507.77B | 3.19% |
Total assets | 1.36T | 7.79% |
Total liabilities | 145.52B | -20.52% |
Total equity | 1.21T | — |
Shares outstanding | 287.33M | — |
Price to book | 0.01 | — |
Return on assets | 7.34% | — |
Return on capital | 8.24% | — |
Cash Flow
Net change in cash
| (JPY) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 36.63B | -63.54% |
Cash from operations | 21.52B | -62.90% |
Cash from investing | 58.06B | 424.16% |
Cash from financing | -50.34B | -11.41% |
Net change in cash | 32.42B | 57.16% |
Free cash flow | -10.37B | -138.52% |
About
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Founded
1878
Headquarters
Website
Employees
5,680
